Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

Relationship Between Cytogenetic Complexity and Peritumoral Edema in High-Grade Astrocytoma.

Jeong KH, Song YJ, Han JY, Kim KU.

Ann Lab Med. 2016 Nov;36(6):583-9. doi: 10.3343/alm.2016.36.6.583.

2.

A small peptide promotes EphA2 kinase-dependent signaling by stabilizing EphA2 dimers.

Singh DR, Pasquale EB, Hristova K.

Biochim Biophys Acta. 2016 Sep;1860(9):1922-8. doi: 10.1016/j.bbagen.2016.06.004. Epub 2016 Jun 6.

PMID:
27281300
3.

Molecularly targeted therapy for the treatment of head and neck cancer: a review of the ErbB family inhibitors.

Sacco AG, Worden FP.

Onco Targets Ther. 2016 Apr 4;9:1927-43. doi: 10.2147/OTT.S93720. eCollection 2016. Review.

4.

One-step tumor detection from dynamic morphology tracking on aptamer-grafted surfaces.

Mahmood MA, Hasan MR, Khan UJ, Allen PB, Kim YT, Ellington AD, Iqbal SM.

Technology (Singap World Sci). 2015 Dec;3(4):194-200. Epub 2015 Nov 16.

5.

Bcl-2 family member Mcl-1 expression is reduced under hypoxia by the E3 ligase FBW7 contributing to BNIP3 induced cell death in glioma cells.

Chen Y, Henson ES, Xiao W, Shome E, Azad MB, Burton TR, Queau M, Sathya A, Eisenstat DD, Gibson SB.

Cancer Biol Ther. 2016 Jun 2;17(6):604-13. doi: 10.1080/15384047.2015.1095399. Epub 2015 Oct 15.

6.
7.

Glioblastoma multiforme: emerging treatments and stratification markers beyond new drugs.

von Neubeck C, Seidlitz A, Kitzler HH, Beuthien-Baumann B, Krause M.

Br J Radiol. 2015 Sep;88(1053):20150354. doi: 10.1259/bjr.20150354. Epub 2015 Jul 10. Review.

8.

Combined epidermal growth factor receptor and Beclin1 autophagic protein expression analysis identifies different clinical presentations, responses to chemo- and radiotherapy, and prognosis in glioblastoma.

Tini P, Belmonte G, Toscano M, Miracco C, Palumbo S, Pastina P, Battaglia G, Nardone V, Butorano MA, Masucci A, Cerase A, Pirtoli L.

Biomed Res Int. 2015;2015:208076. doi: 10.1155/2015/208076. Epub 2015 Mar 3.

9.

Nimotuzumab combined with radiotherapy for esophageal cancer: preliminary study of a Phase II clinical trial.

Liang J, E M, Wu G, Zhao L, Li X, Xiu X, Li N, Chen B, Hui Z, Lv J, Fang H, Tang Y, Bi N, Wang W, Zhai Y, Li T, Chen D, Zou S, Lu N, Perez-Rodríguez R, Zheng J, Wang L.

Onco Targets Ther. 2013 Nov 6;6:1589-96. doi: 10.2147/OTT.S50945. eCollection 2013.

10.

Aberrant signaling pathways in glioma.

Nakada M, Kita D, Watanabe T, Hayashi Y, Teng L, Pyko IV, Hamada J.

Cancers (Basel). 2011 Aug 10;3(3):3242-78. doi: 10.3390/cancers3033242.

11.

Combining molecular targeted agents with radiation therapy for malignant gliomas.

Scaringi C, Enrici RM, Minniti G.

Onco Targets Ther. 2013 Aug 9;6:1079-95. doi: 10.2147/OTT.S48224. eCollection 2013.

12.

RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients.

Chakravarti A, Wang M, Robins HI, Lautenschlaeger T, Curran WJ, Brachman DG, Schultz CJ, Choucair A, Dolled-Filhart M, Christiansen J, Gustavson M, Molinaro A, Mischel P, Dicker AP, Bredel M, Mehta M.

Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):1206-11. doi: 10.1016/j.ijrobp.2012.10.008. Epub 2012 Nov 22.

13.

Targetable "driver" mutations in non small cell lung cancer.

Vijayalakshmi R, Krishnamurthy A.

Indian J Surg Oncol. 2011 Sep;2(3):178-88. doi: 10.1007/s13193-011-0108-0. Epub 2011 Dec 17.

14.

Pediatric high grade glioma: a review and update on tumor clinical characteristics and biology.

Fangusaro J.

Front Oncol. 2012 Aug 24;2:105. doi: 10.3389/fonc.2012.00105. eCollection 2012.

15.

Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies.

Masui K, Cloughesy TF, Mischel PS.

Neuropathol Appl Neurobiol. 2012 Jun;38(3):271-91. doi: 10.1111/j.1365-2990.2011.01238.x. Review.

16.

Molecular diagnostics of gliomas: state of the art.

Riemenschneider MJ, Jeuken JW, Wesseling P, Reifenberger G.

Acta Neuropathol. 2010 Nov;120(5):567-84. doi: 10.1007/s00401-010-0736-4. Epub 2010 Aug 17. Review.

17.

Overexpression of c-erbB2 is a negative prognostic factor in anaplastic astrocytomas.

Gulati S, Ytterhus B, Granli US, Gulati M, Lydersen S, Torp SH.

Diagn Pathol. 2010 Mar 23;5:18. doi: 10.1186/1746-1596-5-18.

18.

Robust detection of EGFR copy number changes and EGFR variant III: technical aspects and relevance for glioma diagnostics.

Jeuken J, Sijben A, Alenda C, Rijntjes J, Dekkers M, Boots-Sprenger S, McLendon R, Wesseling P.

Brain Pathol. 2009 Oct;19(4):661-71. doi: 10.1111/j.1750-3639.2009.00320.x.

19.

Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies.

Diaz Miqueli A, Rolff J, Lemm M, Fichtner I, Perez R, Montero E.

Br J Cancer. 2009 Mar 24;100(6):950-8. doi: 10.1038/sj.bjc.6604943.

20.

Tyrosine phosphorylation of the human glutathione S-transferase P1 by epidermal growth factor receptor.

Okamura T, Singh S, Buolamwini J, Haystead T, Friedman H, Bigner D, Ali-Osman F.

J Biol Chem. 2009 Jun 19;284(25):16979-89. doi: 10.1074/jbc.M808153200. Epub 2009 Mar 2.

Supplemental Content

Support Center